Business

Australia’s CSL reaffirms Reuters’ commitment to producing the AstraZeneca COVID vaccine.

© Reuters. File Photo: In this illustrated photo taken on March 14, 2021, you can see a vial and syringe labeled “AstraZeneca COVID-19 Coronavirus Vaccine” in front of the displayed AstraZeneca logo. .. REUTERS / Dado Ruvic / File Photo

(Reuters)-Australia’s biotechnology CSL announced on Thursday that it had agreed to produce about 50 million doses of AstraZeneca (NASDAQ :) COVID-19 vaccine by 2022.

The announcement came after the media reported that Vaxzevria, a vaccine from a British pharmaceutical company, would no longer be manufactured due to demand for vaccines in Australia. Pfizer (NYSE :) and Modana (NASDAQ :). [nL4N2R91XR]

Pfizer and Modana have established a market advantage by using mRNA-based COVID-19 vaccine technology to combat pandemics.

The CSL added in a brief statement that more than 20 million doses have already been produced and the rest of the production is expected to be completed early next year.

Sydney’s cafes, gyms and restaurants welcomed fully vaccinated customers earlier this week as Australia aims to begin living with the coronavirus and gradually resume with high vaccination rates.

Disclaimer: Fusion media We inform you that the data contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are offered by market makers, not exchanges, so prices may not be accurate and may differ from actual market prices. In other words, price is an indicator and is not suitable for trading purposes. Therefore, Fusion Media is not responsible for any transactional losses that may occur as a result of using this data.

Fusion media Alternatively, anyone involved in Fusion Media will not be liable for any loss or damage resulting from relying on the data, quotes, charts, trading signals and other information contained on this website. Please be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.



Australia’s CSL reaffirms Reuters’ commitment to producing the AstraZeneca COVID vaccine.

Source link Australia’s CSL reaffirms Reuters’ commitment to producing the AstraZeneca COVID vaccine.

Related Articles

Back to top button